Calendar

Arm had a positive EPS-revision backdrop and strong prior-quarter AI-related demand disclosures, but the stock remained sharply weaker over the recent week and failed the required close-location test; elevated down-day turnover adds caution. The company's primary calendar places its event on November 4, one day earlier than the supplied date.

Moderna had a large 2026 oncology-driven re-rating, but the checked sources showed no verified positive Q3 EPS or revenue revision; the quarter remained loss-making by consensus, and the stock's Nov 3 volume was below its cited 20-day average. Recent pipeline enthusiasm does not establish an earnings surprise.

BAM’s Q2 fee-related earnings and distributable earnings growth, alongside fundraising, are constructive operating evidence. However, the checked sources did not establish positive EPS revisions/whisper or revenue revisions. The Nov. 3 close was below Nov. 2 and near the low of its range; the recent high-volume session was a down day rather than convincing accumulation.

HUM's shares rebounded on Nov. 3 and revenue consensus implies growth, but near-term EPS estimates were revised lower with a negative Earnings ESP; steep expected EPS deterioration and Medicare Advantage payment/guidance uncertainty outweigh the price bounce.

The company confirmed its November 6 report date and public estimates exist, but no checked source established positive estimate revisions, ESP/whisper edge, or revenue upside. The pre-event tape was weak into November 2, without a recent high-volume accumulation signal; the prior-quarter reported miss adds execution caution.

CEG shows short-term price recovery into Nov. 3 and a credible third-party estimate of $3.77 EPS and $9.35B revenue, with longer-term demand support from power needs. But the earnings date is not independently confirmed by the checked source, and no positive near-term EPS or revenue revision signal was verified; therefore this is not a qualifying pre-earnings surprise setup.

KKR’s prior quarter beat and strong recent business activity provide some fundamental support, but the checked whisper was below consensus and no positive revenue revision was found. Nov. 3 closed below the prior session and at a weak intraday location; the observed recent high-volume session was a down day, so the tape does not confirm accumulation.

Ferguson confirmed its November 9 report and Earnings Whispers showed an EPS whisper modestly above consensus, while the stock had advanced from late October lows. However, revenue revision/upside was not verified, November 2 volume was below average, and the latest quarter beat EPS but missed revenue; this is an incomplete setup rather than a qualified surprise candidate.

OXY has a meaningful positive EPS revision signal, a $1.60 whisper versus $1.43 consensus, and a four-quarter EPS beat streak. However, the stock sold off sharply on heavy volume, recent closes do not confirm strength, and the checked consensus points to only 0.3% revenue growth without evidence of revenue upside.

The available calendar supplies EPS and revenue consensus but no positive revision or upside evidence, while the combined media business faces significant integration and leverage execution risk; recent tape data do not establish the required close-location or volume signals.

Hugo Boss pops 7% after top shareholder Frasers launches $2 billion takeover offer